Stiripentol

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Stiripentol

Examples of brand names: Diacomit [EU/DE]

ATC code: N03AX17

Main use (for orientation): Dravet syndrome

Documented research summary

Controlled CBD-related stiripentol AUC increase of 55% in healthy people or 30% in epilepsy; in the reverse direction, changes mainly in active CBD metabolites. Distinguish dose and population. Jaisupa 2026, PMID42728549, investigates CBD/7-OH-CBD in human liver microsomes with antiseizure-medication combinations; stiripentol reduces CBD clearance/metabolite formation in vitro, not a clinical individual-pair effect size.

Uncertainties and limitations

PMID42728549 assessed using the original abstract; full-text details and individual combination effects remain unresolved. Not an isolated clinical pair factor.

Separately recorded findings

3 separately recorded findings. Each statement applies to its documented study context.

CBD – clinically studied

Finding ID: B0010

Type of result: Positive finding / indication

Observation: Stiripentol AUC +55%, Cmax +28%.

Mechanism: Probably metabolic inhibition

Study type: Open-label phase I pharmacokinetics

Context studied: Healthy people; pharmaceutical CBD solution 750 mg twice daily plus stiripentol 750 mg twice daily; evaluable pharmacokinetics n=12.

Clinical interpretation: Possible

Limitations and uncertainties: Small healthy cohort with n=12; no direct extrapolation to epilepsy patients. The prose gives 10/13 for an individual Cmax analysis, unlike Tables 3/4; this denominator remains internally unresolved.

Original sources for this finding: A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects [CL03]

CBD – clinically studied

Finding ID: B0011

Type of result: Positive finding / indication

Observation: 7-OH-CBD: AUCtau −28% (geometric mean ratio 0.72; 90% CI 0.61–0.85), Cmax −29% (ratio 0.71; 90% CI 0.51–0.99).

Mechanism: Bidirectional; mechanism not fully resolved

Study type: Open-label phase I pharmacokinetics

Context studied: Stiripentol → CBD metabolite; both 750 mg twice daily; pharmacokinetic n=12.

Clinical interpretation: Unclear

Limitations and uncertainties: No pronounced change in CBD parent substance.

Original sources for this finding: A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects [CL03]

CBD – clinically studied

Finding ID: B0016

Type of result: Positive finding / indication

Observation: AUC +30%, Cmax +17%.

Mechanism: Metabolic inhibition plausible

Study type: Randomised phase II pharmacokinetics

Context studied: Epilepsy; CBD 20 mg/kg/day. 35 randomised, 34 in the safety sample; stiripentol arm n=14 (12 CBD, 2 placebo), evaluable paired CBD treatment effect n=9 (Fig. 4).

Clinical interpretation: Rather low/unclear

Limitations and uncertainties: Small stiripentol subgroup.

Original sources for this finding: A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy [CL05]

References and access status

[CA_L_D0053] DIACOMIT (STIRIPENTOL) CAPSULE DIACOMIT (STIRIPENTOL) POWDER, FOR SUSPENSION [BIOCODEX, INC.]

Original source / bibliographic reference

Authors: BIOCODEX, INC.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL03] A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

Original source / bibliographic reference

Authors: Morrison G; Crockett J; Blakey G; Sommerville K

Year: 2019

Source type: Open-label phase I study with a fixed sequence

DOI: 10.1002/cpdd.665

PMID: 30791225

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CL05] A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy

Original source / bibliographic reference

Authors: Ben-Menachem E; Gunning B; Arenas Cabrera CM; VanLandingham K; Crockett J; Critchley D; Wray L; Tayo B; Morrison G; Toledo M

Year: 2020

Source type: Randomised phase II study

DOI: 10.1007/s40263-020-00726-4

PMID: 32350749

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_40315023] Cannabidiol metabolism in vitro: the role of antiseizure medications and CYP2C19 genotypes.

Original source / bibliographic reference

Authors: Jaisupa N, Ashton M, Birgersson S.

Year: 2025

Source type: Journal Article

DOI: 10.1080/00498254.2025.2498696

PMID: 40315023

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_42728549] Potential Role of CYP3A4 in Determining In Vivo Exposure to Cannabidiol (CBD) and its Active Metabolite 7-OH-CBD: Evidence from an In Vitro Study.

Original source / bibliographic reference

Authors: Jaisupa N, Birgersson S, Ashton M.

Year: 2026

Source type: Journal Article

DOI: 10.1007/s13318-026-01032-y

PMID: 42728549

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility